Back to Journals » Drug Design, Development and Therapy » Volume 11

Targeted therapy in severe asthma today: focus on immunoglobulin E

Authors Pelaia G, Canonica GW, Matucci A, Paolini R, Triggiani M, Paggiaro P

Received 20 December 2016

Accepted for publication 8 March 2017

Published 29 June 2017 Volume 2017:11 Pages 1979—1987

DOI https://doi.org/10.2147/DDDT.S130743

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Akshita Wason

Peer reviewer comments 2

Editor who approved publication: Dr Sukesh Voruganti

Girolamo Pelaia,1 Giorgio Walter Canonica,2 Andrea Matucci,3 Rossella Paolini,4 Massimo Triggiani,5 Pierluigi Paggiaro6

1Department of Medical and Surgical Sciences, Section of Respiratory Diseases, University Magna Graecia of Catanzaro, Catanzaro, 2Personalized Medicine Asthma & Allergy Clinic, Humanitas University, IRCCS Humanitas Research Hospital, Rozzano-Milano, 3Immunoallergology Unit, AOU Careggi, Florence, 4Department of Molecular Medicine, “Sapienza” University of Rome, Laboratory affiliated to Istituto Pasteur Italia – Fondazione Cenci Bolognetti, Rome, 5Division of Allergy and Clinical Immunology, University of Salerno, Salerno, 6Cardio Thoracic and Vascular Department, Pathophysiology Unit, University of Pisa, Pisa, Italy

Abstract: Asthma is a complex chronic inflammatory disease of multifactorial etiology. International guidelines increasingly recognize that a standard “one size fits all” approach is no longer an effective approach to achieve optimal treatment outcomes, and a number of disease phenotypes have been proposed for asthma, which has the potential to guide treatment decisions. Among the many asthma phenotypes, allergic asthma represents the widest and most easily recognized asthma phenotype, present in up to two-thirds of adults with asthma. Immunoglobulin E (IgE) production is the primary and key cause of allergic asthma leading to persistent symptoms, exacerbations and a poor quality of life. Therefore, limiting IgE activity upstream could stop the entire allergic inflammation cascade in IgE-mediated allergic asthma. The anti-IgE treatment omalizumab has an accepted place in the management of severe asthma (Global Initiative for Asthma [GINA] step 5) and represents the first (and, currently, only) targeted therapy with a specific target in severe allergic asthma. This review summarizes current knowledge of the mechanisms and pathogenesis of severe asthma, examines the actual role of IgE in asthma and the biological rationale for targeting IgE in allergic asthma and reviews the data for the efficacy and safety of omalizumab in the treatment of severe asthma. Current knowledge of the role of IgE in asthma, extensive clinical trial data and a decade of use in clinical practice has established omalizumab as a safe and effective targeted therapy for the treatment of patients with severe persistent IgE-mediated allergic asthma.

Keywords: anti-immunoglobulin E, allergic asthma, Global Initiative for Asthma step 5 therapy, severe persistent asthma, omalizumab, phenotypes, targeted therapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab

Pelaia C, Vatrella A, Busceti MT, Gallelli L, Terracciano R, Savino R, Pelaia G

Drug Design, Development and Therapy 2017, 11:3137-3144

Published Date: 30 October 2017

Role of biologics in severe eosinophilic asthma – focus on reslizumab

Pelaia G, Vatrella A, Busceti MT, Gallelli L, Preianò M, Lombardo N, Terracciano R, Maselli R

Therapeutics and Clinical Risk Management 2016, 12:1075-1082

Published Date: 1 July 2016

Pharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPD

Pelaia G, Vatrella A, Busceti MT, Gallelli L, Calabrese C, Terracciano R, Lombardo N, Maselli R

Therapeutics and Clinical Risk Management 2015, 11:1563-1572

Published Date: 8 October 2015

Update on optimal use of omalizumab in management of asthma

Pelaia G, Gallelli L, Renda T, Romeo P, Busceti MT, Grembiale RD, Maselli R, Marsico SA, Vatrella A

Journal of Asthma and Allergy 2011, 4:49-59

Published Date: 13 June 2011